Primary thyroid dysfunction (n = 93) | Secondary thyroid dysfunction (n = 20) | P | t/ x2/Z | |
---|---|---|---|---|
Gender (n, %) | 0.264 | 1.247 | ||
Male | 68(73.1) | 17(85.0) | ||
Female | 25(26.9) | 3(15.0) | ||
Age(years,x ± s) | 58.0 ± 10.7 | 61.6 ± 9.9 | 0.174 | 1.368 |
BMI | 22.1 ± 2.7 | 23.6 ± 3.5 | 0.132 | 1.520 |
Diabetes | 1.000 | 0.000 | ||
Yes | 15(16.1) | 3(15.0) | ||
No | 78(83.9) | 17(85.0) | ||
Evaluation time [weeks,M(Q1,Q3)] | 12.0(3.0, 27.8) | 10.0(3.3, 17.8) | 0.412 | 0.821 |
Hepatocellular carcinoma (n,%) | 0.936 | 0.007 | ||
Yes | 87(93.5) | 18(90.0) | ||
No | 6(6.5) | 2(10.0) | ||
Staging of BCLC system(n,%) | 0.350 | 0.875 | ||
B | 19(20.4) | 6(30.0) | ||
C | 74(76.0) | 14(70.0) | ||
HBV or HCV(n,%) | 83(77.4) | 19(85.0) | 0.710 | 0.138 |
Cirrhosis (n,%) | 74(80.5) | 18(87.8) | 0.441 | 0.595 |
Decompensation stage (n,%) | 27(36.5) | 15(83.3) | 0.002 | 9.166 |
Yes | 41(63.5) | 3(16.7) | ||
No | ||||
Previous or combined treatment (n,%) | 15(16.1) | 1(5.0) | 0.346 | 0.887 |
Surgical resection | 69(74.2) | 16(80.0) | 0.795 | 0.086 |
TAE or TACE | 43(46.2) | 12(60.0) | 0.264 | 1.248 |
Tumor ablation | 68(73.1) | 9(45.0) | 0.014 | 5.995 |
Targeted agent | 5(5.4) | 1(5.0) | 1.000 | 0.000 |
Systemic chemotherapy | 12(12.9) | 2(10.0) | 1.000 | 0.000 |
Radiotherapy | 12(12.9) | 1(5.0) | 0.536 | 0.383 |
Name of PD-1 monoclonal antibody (n,%) | 0.319 | 0.992 | ||
Sintilimab | 50(53.8) | 9(45.0) | ||
Camrelizumab | 43(46.2) | 11(55.0) | ||
Thyroid antibody (n,%) | 0.036 | - | ||
Positive | 7(31.8) | 0(0.0) | ||
Negative | 15(68.2) | 12(100.0) |